CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenues:
Collaboration revenue	$ 40,023	$ 145	$ 41,144	$ 1,512
Royalty income	1,626	719	3,728	3,052
Research grants	0	0	0	275
Other revenues	7	3	76	55
Total revenues	41,656	867	44,948	4,894
Expenses:
Research and development	6,728	7,905	21,495	26,205
License fees - research and development	10	91	280	314
Royalty expense	319	73	548	308
General and administrative	3,895	3,131	11,156	11,350
Depreciation and amortization	142	179	419	774
Intangible impairment charge	576	0	576	0
Change in contingent consideration liability	500	0	1,400	0
Total expenses	12,170	11,379	35,874	38,951
Other Operating Income	7,250	0	7,250	0
Operating income (loss)	36,736	(10,512)	16,324	(34,057)
Other income:
Interest income	12	12	37	36
Total other income	12	12	37	36
Net income (loss) before income tax benefit	36,748	(10,500)	16,361	(34,021)
Income tax benefit	227	0	228	0
Net income (loss)	$ 36,975	$ (10,500)	$ 16,589	$ (34,021)
Net income (loss) per share - basic	$ 0.53	$ (0.17)	$ 0.24	$ (0.63)
Weighted-average shares - basic	69,556	60,599	67,712	54,104
Net income (loss) per share - diluted	$ 0.51	$ (0.17)	$ 0.24	$ (0.63)
Weighted-average shares - diluted	72,879	60,599	67,727	54,104